Associated Genetic Biomarkers
ROS1 G2032R is present in 0.00% of AACR GENIE cases.
ROS1 G2032R is a predictive biomarker for use of crizotinib in patients.
Non-small cell lung carcinoma has the most therapies targeted against ROS1 G2032R or its related pathways .
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Acquired Resistance|
|Clinical Setting(s): Metastatic (MCG)|
|Note: ROS1 D2033N and ROS1 G2032R have been identified as resistance mutations in patients treated with crizotinib. For more information, see Gainor, J., et al., 2017 (PMID: 29333528).|
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.